Business, energy, technology, markets and global industry news from Business News Today

tonlamarsen

PharmaDeviceNews tonlamarsen
Representative image of cardiovascular drug research as Kardigan’s planned Nasdaq IPO puts precision heart medicines, late-stage clinical trials, and biotech investor appetite under sharper focus.
Pharma & Biotech

Kardigan’s $1.4bn IPO plan tests investor appetite for late-stage cardiovascular biotech

Find out how Kardigan’s planned Nasdaq IPO could reshape precision cardiovascular drug development and biotech investor sentiment.

Read More
Representative image of blood pressure research and cardiovascular drug development, illustrating Kardigan’s tonlamarsen Phase 2 hypertension study and the growing focus on acute severe hypertension treatment.
Pharma & Biotech

Why Kardigan’s Phase 2 tonlamarsen results matter more for acute severe hypertension than chronic blood pressure care

Kardigan’s tonlamarsen showed Phase 2 promise in hypertension, but can it win in acute severe hypertension next? Read the deeper analysis.

Read More